Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Camphikefishon Feb 06, 2024 4:45pm
360 Views
Post# 35866210

Take home message?

Take home message?Enrique and Apop and all the other gurus here. I want to make sure I'm getting the "take home message" right. What makes us shine when compared to CG Oncology is the simple fact that we are achieving very close to the same results with only 1-2 treatments right? They require many more treatments to arrive at the CR numbers they have achieved if I'm understanding this correctly. Furthermore, we have yet to see their longer term efficacy results and we are at least able to look out to 450 days with some of our patients. Again with only 1-2 treatments. So who knows what numbers we might see with multiple treatments in the future. Having said these things we should be very attractive to a partner out there should we also receive a patent for an immunicological intravenous approach I would hope as a combined treatment. Just thinking out loud to see how you folks see us stacking up against the closest competitor. Thank you for any insight and clarification and comments! 
<< Previous
Bullboard Posts
Next >>